Complement activation and effect of eculizumab in scleroderma renal crisis.
about
Complement C5-inhibiting therapy for the thrombotic microangiopathies: accumulating evidence, but not a panacea.Scleroderma Renal Crisis Debute with Thrombotic Microangiopathy: A Successful Case Treated with EculizumabAtypical rapid onset Scleroderma Renal Crisis (SRC) complicated with diffuse alveolar hemorrhage and pleuro-pericardial effusions in a patient with recently diagnosed breast cancer and a positive anti-RNA polymerase III Ab.: A case report
P2860
Complement activation and effect of eculizumab in scleroderma renal crisis.
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on July 2016
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
Complement activation and effect of eculizumab in scleroderma renal crisis.
@en
Complement activation and effect of eculizumab in scleroderma renal crisis.
@nl
type
label
Complement activation and effect of eculizumab in scleroderma renal crisis.
@en
Complement activation and effect of eculizumab in scleroderma renal crisis.
@nl
prefLabel
Complement activation and effect of eculizumab in scleroderma renal crisis.
@en
Complement activation and effect of eculizumab in scleroderma renal crisis.
@nl
P2093
P2860
P1433
P1476
Complement activation and effect of eculizumab in scleroderma renal crisis
@en
P2093
Arnaud Devresse
Catherine Lambert
Johann Morelle
Michel Jadoul
Nathalie Demoulin
Patrick Stordeur
Sara Gastoldi
Selda Aydin
Yves Pirson
P2860
P356
10.1097/MD.0000000000004459
P407
P577
2016-07-01T00:00:00Z